NICM
DYN icon

Neo Ivy Capital Management’s Dyne Therapeutics DYN Stock Holding History

Neo Ivy Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698K Sell
31,440
-137,313
-81% -$2.55M 0.16% 196
2026
Q1 		$3.06M Sell
168,753
-68,714
-29% -$1.18M 0.81% 25
2025
Q4 		$4.64M Buy
+237,467
New +$4.5M 0.73% 44
2025
Q1 		– Sell
-8,715
Closed -$205K – 324
2024
Q4 		$205K Buy
+8,715
New +$258K 0.04% 220

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Neo Ivy Capital Management's DYN Position: Q2 2026 in Review

Neo Ivy Capital Management reduced its Dyne Therapeutics (DYN) stake by 81% in Q2 2026, selling an estimated $2.55M and leaving 31,440 shares worth $698K. The position accounts for 0.16% of the portfolio, ranked #196.

Neo Ivy Capital Management first reported a position in DYN in Q4 2024 and has held it in 4 quarters since. The position peaked at $4.64M in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Neo Ivy Capital Management held 31,440 shares of Dyne Therapeutics worth $698K as of Q2 2026.
  • Neo Ivy Capital Management sold 137,313 Dyne Therapeutics shares in Q2 2026, an estimated $2.55M.
  • Dyne Therapeutics made up 0.16% of Neo Ivy Capital Management's portfolio in Q2 2026, its #196 holding.
  • Neo Ivy Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Neo Ivy Capital Management's Dyne Therapeutics position peaked at $4.64M in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.